지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Large, randomized, controlled trials have demonstrated the efficacy of bisphosphonates (BP) in terms of improving bone mineraldensity (BMD) and reducing fracture risk. Consequently, bisphosphonates are used widely in the treatment of osteoporosis.
Recently, however, several safety issues regarding the long-term use of BP, especially BP-related osteonecrosis of the jaws andatypical fractures, have been noted and have emerged as a limitation of their clinical use. Although the absolute risk is very small,the risks could increase with the long-term use of BP. The anti-fracture efficacy of BP is not sustained after treatment for 5-10 years.
Therefore, recommendations suggest that a drug holiday be considered after 5 years of treatment for patients at low risk of fracture.
However, as the individual fracture risk varies, the treatment duration should be based on individual clinical risk factors and bonemetabolism status. Moreover, recommendations regarding monitoring after discontinuing and reinitiating BP await further studies.
목차
등록된 정보가 없습니다.
참고문헌 (21)
참고문헌 신청
Black DM / 2006 / Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial /
Black DM / 2012 / Continuing bisphosphonate treatment for osteoporosis: for whom and for how long / N Engl J Med 366 : 2051 ~ 2053
Black DM / 2012 / The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) / J Bone Mi
Bliuc D / 2009 / Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women / JAMA 301 : 513 ~ 521
Center JR / 1999 / Mortality after all major types of osteoporotic fracture in men and women: an observational study / Lancet 353 : 878 ~ 882
Black DM / 2012 / Continuing bisphosphonate treatment for osteoporosis: for whom and for how long / N Engl J Med 366 : 2051 ~ 2053
Black DM / 2012 / The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) / J Bone Mi
Bliuc D / 2009 / Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women / JAMA 301 : 513 ~ 521
Center JR / 1999 / Mortality after all major types of osteoporotic fracture in men and women: an observational study / Lancet 353 : 878 ~ 882
이 논문의 저자 정보
최근 본 자료
댓글(0)
0